A selective HK2 degrader suppresses SW480 cancer cell growth by degrading HK2

被引:0
|
作者
Yang Liu [1 ]
Yan Liu [2 ]
Kaiyin Yang [3 ]
Zhiruo Zhang [1 ]
Wenbo Zhang [1 ]
Bingyou Yang [2 ]
Hua Li [1 ,4 ]
Lixia Chen [1 ]
机构
[1] Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University
[2] Key Laboratory of Basic and Application Research of Beiyao, Ministry of Education, Heilongjiang University of Chinese Medicine
[3] Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology
[4] Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Hexokinase 2(HK2) is the rate-limiting enzyme in the first step of glycolysis, catalyzing glucose to glucose-6-phosphate, and overexpressed in most cancer cells. HK2 also binds to voltage-dependent anion channel(VDAC) to stabilize the mitochondrial outer membrane, which inhibits cancer cell apoptosis.Therefore, HK2 has become a potential target for cancer treatment. Proteolysis targeting chimeras(PROTACs) are hetero-bifunctional molecules that recruit an E3 ubiquitin ligase to a given substrate protein resulting in its targeted degradation. Many potent and specific PROTACs targeting dissimilar targets have been developed. In this study, an HK2 PROTAC, 4H-5P-M, was developed and induced the degradation of HK2 relying on the ubiquitin-proteasome system. It was found that 4H-5P-M as an effective HK2 degrader induced HK2 degradation in a dose-and time-dependent manner and suppressed the growth of SW480 cells. 4H-5P-M selectively induced HK2 degradation at a lower concentration than other hexokinase isozymes. Moreover, it could suppress glycolysis and accelerate the apoptosis of cancer cells. Therefore, it provided a new insight into the development of anti-tumor drugs.
引用
收藏
页码:228 / 231
页数:4
相关论文
共 50 条
  • [21] Downregulation of HK2 by lentiviral shRNA improve radiosensitivity of breast cancer
    Zhang, Dan
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [22] Hexokinase II (HK2) regulates stemness of ovarian cancer cells
    Jiang, Yuxin
    Siu, Michelle K. Y.
    Wang, Jingjing
    Leung, Thomas H. Y.
    Cheung, Annie N. Y.
    Ngan, Hextan Y. S.
    Chan, Karen K. L.
    CANCER RESEARCH, 2017, 77
  • [23] Expression of human glandular kallikrein, hK2, in cells
    Kumar, A
    Goel, AS
    Hill, TM
    Mikolajczyk, SD
    Millar, LS
    KuusReichel, K
    Saedi, MS
    CANCER RESEARCH, 1996, 56 (23) : 5397 - 5402
  • [24] ORY-1001 Suppresses Cell Growth and Induces Apoptosis in Lung Cancer Through Triggering HK2 Mediated Warburg Effect
    Lu, Zhaoliang
    Guo, Yanke
    Zhang, Xiaoya
    Li, Jing
    Li, Leilei
    Zhang, Shuai
    Shan, Changliang
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [25] Methylprednisolone reduces TNF-α-mediated HK2 cell necrosis
    Gupta, R
    McBride, WT
    McLay, J
    McMurray, TJ
    Armstrong, MA
    BRITISH JOURNAL OF ANAESTHESIA, 2003, 91 (03) : 462P - 462P
  • [26] Can prostatic kallikrein hK2 favor prostatic cancer progression?
    Dube, JY
    M S-MEDECINE SCIENCES, 1998, 14 (01): : 111 - 113
  • [27] miR-3662 suppresses cell growth, invasion and glucose metabolism by targeting HK2 in hepatocellular carcinoma cells
    Ye, J.
    Xiao, X.
    Han, Y.
    Fan, D.
    Zhu, Y.
    Yang, L.
    NEOPLASMA, 2020, 67 (04) : 773 - 781
  • [28] Role of HK2 in the Enzootic Cycle of Borrelia burgdorferi
    Liu, Qiang
    Xu, Haijun
    Zhang, Yan
    Yang, Jing
    Du, Jimei
    Zhou, Yan
    Yang, X. Frank
    Lou, Yongliang
    FRONTIERS IN MEDICINE, 2020, 7
  • [29] Novel peptide inhibitors of human kallikrein 2 (hK2)
    Hekim, C
    Stenman, UH
    Narvanen, A
    Leinonen, J
    FEBS JOURNAL, 2005, 272 : 169 - 169
  • [30] Therapeutic efficacy of ECs Foxp1 targeting Hif1α-Hk2 α-Hk2 glycolysis signal to restrict angiogenesis
    Pi, Jingjiang
    Chang, Huan
    Chen, Xiaoli
    Pan, Wenqi
    Zhang, Qi
    Zhuang, Tao
    Liu, Jiwen
    Wang, Haikun
    Tomlinson, Brian
    Chan, Paul
    Cheng, Yu
    Yu, Zuoren
    Zhang, Lin
    Zhao, Zhenlin
    Liu, Zhongmin
    Liu, Jie
    Zhang, Yuzhen
    REDOX BIOLOGY, 2024, 75